SCM
LXEO icon

Silverarc Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

Silverarc Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-617,608
Closed -$6.13M – 81
2025
Q4 		$6.13M Sell
617,608
-161,003
-21% -$1.47M 0.85% 32
2025
Q3 		$5.17M Buy
+778,611
New +$3.77M 0.7% 39

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Silverarc Capital Management's LXEO Position: Q1 2026 in Review

Silverarc Capital Management sold out of Lexeo Therapeutics (LXEO) in Q1 2026, closing a stake of 617,608 shares — an estimated $6.13M sold.

Silverarc Capital Management first reported a position in LXEO in Q3 2025 and held it in 2 quarters. The position peaked at $6.13M in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Silverarc Capital Management reported no remaining Lexeo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Silverarc Capital Management sold 617,608 Lexeo Therapeutics shares in Q1 2026, an estimated $6.13M.
  • Silverarc Capital Management first reported a position in Lexeo Therapeutics in Q3 2025 and held it in 2 quarters.
  • Silverarc Capital Management's Lexeo Therapeutics position peaked at $6.13M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.